RBC expects a third-quarter revenue beat for Bristol Myers Squibb stock

Published on 10/20/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC kept its USD 64.00 target on October 19, 2026. Bristol Myers Squibb stock has results scheduled for October 29, 2026.

Quarterly catalyst and valuation

RBC maintained a USD 64.00 target on October 19, 2026.
Second-quarter revenue reached USD 12.97 billion in 2026.
Bristol Myers Squibb stock traded at EUR 52.74 at 11:04 a.m. CEST at Lang & Schwarz on October 20, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) is heading toward a third-quarter test after RBC kept a USD 64.00 target and said revenue could beat estimates in a note dated October 19, 2026. Fidelity reported that RBC cited stronger sales of Eliquis, Revlimid, Breyanzi and Reblozyl.

Three dates shape the setup

On July 30, 2026, Bristol Myers Squibb reported second-quarter revenue of USD 12.97 billion, up 5.7 percent year over year, while diluted earnings per share reached USD 1.62. TickerScout also reported net earnings of USD 3.32 billion, up 153.2 percent. On October 5, 2026, Leerink Partners cut its target from USD 73.00 to USD 59.00, according to MarketBeat. On October 19, 2026, RBC maintained its Sector Perform rating and USD 64.00 target.

What does October 29 mean?

The next report will test whether the growth portfolio can offset pressure on established products. RBC expects a third-quarter revenue beat, while its USD 64.00 target sits above the latest US market quote of USD 58.83 from October 19, 2026. Bristol Myers Squibb's second-quarter growth provides a measurable starting point: revenue increased from USD 12.27 billion a year earlier to USD 12.97 billion. The company also raised its full-year 2026 revenue guidance to USD 49.0 billion to USD 50.0 billion and adjusted earnings guidance to USD 6.75 to USD 7.00, according to TickerScout.

Next reporting date

Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026, with the conference call set for 8:00 a.m. ET, according to the company's investor calendar at Bristol Myers Squibb.

Stock valuation remains mixed

The valuation picture combines a fresh operating catalyst with a wide range of analyst views. The latest US market capitalization was USD 120.2 billion as of October 19, 2026, while the share price stood below RBC's target and above the USD 41.00 low target cited in recent analyst coverage. The company is listed on the NYSE under BMY, as shown on its investor page. At Lang & Schwarz, Bristol Myers Squibb stock was trading intraday at EUR 52.74 on October 20, 2026 at 11:04 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.